RLMD | Relmada Therapeutics, Inc. Annual & Quarterly

Annual Income Statements

(In USD)

Breakdown	2023	2022	2021	2020	2019	2019
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	1258.00	3752.00	-	4870.00
Gross Profit	-	-	-1258.00	-3752.00	-	-4870.00
Operating Expenses	103.7 Million	161.24 Million	125.7 Million	60.83 Million	15.1 Million	12.72 Million
Selling, General and Administrative Expenses	48.89 Million	47.92 Million	35.08 Million	24.86 Million	7.24 Million	5.7 Million
Research and Development Expenses	54.8 Million	113.32 Million	90.62 Million	35.97 Million	7.85 Million	7.02 Million
Other Expenses	-293.00	6.35 Million	-	-	-	-
Cost and Expenses	103.7 Million	161.24 Million	125.7 Million	60.83 Million	15.1 Million	12.72 Million
Operating Income	-103.7 Million	-161.24 Million	-125.7 Million	-60.83 Million	-15.1 Million	-12.72 Million
Interest Expense	-	-	-	-	-	-
Income Tax Expense	-	-2.65 Million	48.31 Thousand	-1.38 Million	-1.00	4.59 Million
Earnings before Tax	-98.79 Million	-157.04 Million	-125.75 Million	-59.45 Million	-15 Million	-17.31 Million
Net Income	-98.79 Million	-157.04 Million	-125.75 Million	-59.45 Million	-15 Million	-17.31 Million
Earnings Per Share Basic	-3.28	-5.30	-7.16	-3.81	-1.63	-2.74
Earnings Per Share Diluted	-3.28	-5.30	-7.16	-3.81	-1.63	-2.74
Weighted Average Shares Outstanding	30.09 Million	29.62 Million	17.55 Million	15.59 Million	9.22 Million	6.31 Million
Weighted Average Shares Outstanding (Diluted)	30.09 Million	29.62 Million	17.55 Million	15.59 Million	9.22 Million	6.31 Million
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	4.91 Million	-157.04 Million	-125.75 Million	-59.45 Million	-15.1 Million	-16.55 Million
Earnings Before Tax Margin	-	-	-	-	-	-

Breakdown	2024 Q2	2024 Q1	2023 FY	2023 Q4	2023 Q3	2023 Q2
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	18.81 Million	22.98 Million	103.7 Million	26.82 Million	22.69 Million	26.02 Million
Selling, General and Administrative Expenses	8.09 Million	9.68 Million	-	12.07 Million	12.23 Million	12.28 Million
Research and Development Expenses	10.72 Million	13.3 Million	-	14.75 Million	10.45 Million	13.74 Million
Other Expenses	-	-	-	-	-	-
Cost and Expenses	18.81 Million	22.98 Million	103.7 Million	26.82 Million	22.69 Million	26.02 Million
Operating Income	-18.81 Million	-22.98 Million	-103.7 Million	-26.82 Million	-22.69 Million	-26.02 Million
Interest Expense	-	-	-	-	-	-
Income Tax Expense	-18.81 Million	-22.98 Million	-103.7 Thousand	-26.82 Thousand	-1.32 Million	-1.36 Million
Earnings before Tax	-17.76 Million	-21.82 Million	-98.79 Million	-25.16 Million	-22 Million	-25.3 Million
Net Income	-17.76 Million	-21.82 Million	-98.79 Million	-25.16 Million	-22 Million	-25.3 Million
Earnings Per Share Basic	-0.59	-0.72	-	-0.84	-0.73	-0.84
Earnings Per Share Diluted	-0.59	-0.72	-	-0.84	-0.73	-0.84
Weighted Average Shares Outstanding	30.17 Million	30.13 Million	30.09 Million	30.09 Million	30.09 Million	30.09 Million
Weighted Average Shares Outstanding (Diluted)	30.17 Million	30.13 Million	30.09 Million	30.09 Million	30.09 Million	30.09 Million
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-18.81 Million	-22.98 Million	-	-26.82 Million	-22.06 Million	-25.38 Million
Earnings Before Tax Margin	-	-	-	-	-	-